Skip to main content
. Author manuscript; available in PMC: 2019 Mar 28.
Published in final edited form as: J Control Release. 2018 Jan 31;274:24–34. doi: 10.1016/j.jconrel.2018.01.028

Figure 5.

Figure 5

A. schemetic representation of F(ab′)2 antibody ligation to PLGA-PEG polymeric nanoparticles through thiol-maliamide chemistry. B Scheme of antibody fragment conjugation to the surface of pre-formulated maleimide-functionalized PEG-PLGA polymeric nanoparticles (NPs). B Scanning electron microscopy images showed the nanoparticulate nature of free and antibody conjugated nanoparticle. C. Tumor growth inhibiton of TLR7/8 agonist encapsulated anti-PD-1 PLGA-PEG nanoparticle than combination of individual components. D. Smilarlt, significant improvement survial rate in nanoformulation encapsulated with TGFβ inhibitor (SD-208). These data demonstrate the superiority of nanoformulation for improving current cancer immunothrapy with least side effect. Images were reproduced form ref. [85].